Myriad Presents Two New Studies at the Western Section of the American Urological Association

Myriad Genetics (NASDAQ:MYGN), a global leader in personalized medicine, today announced new data from two studies presented at the Western Section of the American Urological Association annual meeting in Maui, HI.

As quoted in the press release:

The key results are that the Prolaris^® test is superior to adverse pathology at predicting the risk of prostate cancer biochemical recurrence after surgery, and the myRisk^® Hereditary Cancer test found one in ten men with prostate cancer carry an inherited genetic mutation in a cancer-causing gene.

“Myriad Genetics is committed to advancing personalized medicine and providing urologists with genetic information to enable better care and outcomes for their patients with prostate cancer.” said Todd Cohen, M.D., vice president of Medical Affairs, Myriad Urology.  “At this conference, our collaborators presented two new studies that highlight important clinical benefits of the Prolaris and myRisk Hereditary Cancer tests and provide useful information on how these tests can be used to help guide patient care.”

Click here to read the full press release.